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Meta-analyses combining gene expression microarray experiments offer new insights into the
molecular pathophysiology of disease not evident from individual experiments. Although the
established technical reproducibility of microarrays serves as a basis for meta-analysis,
pathophysiological reproducibility across experiments is not well established. In this study, we
carried out a large-scale analysis of disease-associated experiments obtained from NCBI GEO, and
evaluated their concordance across a broad range of diseases and tissue types. On evaluating 429
experiments, representing 238 diseases and 122 tissues from 8435microarrays, we find evidence for
a general, pathophysiological concordance between experiments measuring the same disease
condition. Furthermore, we find that the molecular signature of disease across tissues is overall
more prominent than the signature of tissue expression across diseases. The results offer new
insight into the quality of publicmicroarray data using pathophysiologicalmetrics, and support new
directions in meta-analysis that include characterization of the commonalities of disease
irrespective of tissue, as well as the creation of multi-tissue systems models of disease pathology
using public data.
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Introduction
Aggregate analysis of gene expression microarrays (Lipshutz
et al, 1995; Schena et al, 1995) across multiple studies is
lending an unprecedented molecular view of the broad
spectrum of human disease (Alizadeh et al, 2000; Golub
et al, 1999). Ramaswamy et al (2003) were among the first to
show how a taxonomy of cancers could be created after
building a reference collection of gene expression profiles for
multiple types of cancers. This approach was extended to find
common changes in gene expression across publicly available
cancermicroarray experiments (Rhodes et al, 2004). Segal et al
(2004) integrated 1975 microarrays, representing 22 tumor
types, to uncover a ‘module map’ of gene modules with
conditional expression patterns across tumor types. Despite
these successes, the considerable variation inherent to
microarray data greatly confounds efforts to integrate data
across multiple experiments.
There have been a number of efforts to characterize and
mitigate potentially confounding, non-biological sources of
variance in microarray data. In 2006, the Microarray Quality
Control Consortium (MAQC) showed that measurements are
technically reproducible across test sites and manufacturer
(Shi et al, 2006). It was shown that lab-to-lab variation imparts
a significant effect onmicroarray measurements (Irizarry et al,
2005), however, a number of robust methods to handle such
variation have been developed (Breitling et al, 2004; Choi et al,
2007; Huttenhower et al, 2006; Pihur et al, 2008; Zilliox and
Irizarry, 2007). Although these efforts lend credence to the
technical equivalence of microarray data across experiments,
the biological equivalence of microarray data across experi-
ments is not well characterized.
A recent study suggests that gene expression measurements
can be combined to gain new biological insights that are
relevant beyond their original experimental context. Bild et al
(2006) built a collection of genome-wide changes in breast
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cancer cell lines in response to the overexpression of several
oncogenes, then used these to probe public microarray
measurements of other types of cancers. Similarly, Lamb
et al (2006) built a larger collection of responses in human
breast cancer cell lines toward 164 different small molecules,
then used these to probe previously unexplainable gene
expression changes in completely different tissues and
diseases, finding agonists with responses equivalent to a
diet-induced obesity model in rat fat cells. These studies
suggest that the signature of a disease is robust irrespective of
the tissue in which it was studied, however, the generalization
of this phenomenon across all of human disease has not been
established. To fully evaluate such a hypothesis requires a
sufficiently large and diverse collection of microarray data for
human diseases.
Public microarray data repositories have emerged as
enabling resources for the integrative genomic study of human
disease (Rhodes and Chinnaiyan, 2005). Coincident with their
successful use, and because many journals require the public
availability of such data (Anonymous, 2002), the amount of
microarray data in international repositories is now growing
exponentially (Parkinson et al, 2009). The largest among these
is the National Center for Biotechnology Information (NCBI)
Gene Expression Omnibus (GEO) (Wheeler et al, 2006). As of
this writing, GEO holds information on4300 000 samples (i.e.
microarrays) from412000 experiments, and doubles in size
each year. Enabled by the vast repertoire of GEO experiments
studying numerous human diseases (e.g. diabetes) across a
broad diversity of tissues types (e.g. muscle and fat), we can
pose an important question in integrative biology: is there a
general disease concordance across public microarray experi-
ments irrespective of platform and tissue? In this study, we
carried out a systematic evaluation of disease-associated
experiments in GEO to evaluate the robustness of the disease
signal across tissues and experiments.
To ensure our findings were robust and unbiased towards
any specific choice of analytic methodology, we designed a
computational ‘pipeline’ using 84 combinations of normal-
ization, probe-level integration, and significance testing
methods (Box 1). We find that there is a general concordance
between disease states across tissues, irrespective of other
confounding sources of biological or technical variation
inherent in the data. Furthermore, we find that this disease
concordance is more prominent than other potentially
concordant biological factors, such as tissue type. Our results
raise several important implications for the downstream
translational research value of public microarray data in
building systematic models of disease pathogenesis, prog-
nosis, and treatment.
Results and discussion
Discovery and annotation of disease-associated
microarray experiments
To evaluate the hypothesis of disease concordance across
microarray experiments, we first assembled a large data set of
disease-associated microarray experiments from NCBI GEO
Box 1 The full complement of 429 disease-associated microarray experiments was repeatedly evaluated by the pipeline under all 84 possible combinations of
pipeline parameters to comprehensively evaluate the robustness of disease signatures.
Box 1 Schematic diagram for the pipeline used to evaluate disease concordance across public microarray experiments
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and systematically annotated each experiment to codify the
disease and tissue conditions that were measured. This
process identified 429 disease-associated experiments that
measured both a disease and normal control state, represent-
ing 238 unique diseases measured in 122 distinct tissues. In
total, these experiments yielded 429 diseases versus control
comparisons that were associated with 8435 microarray
samples comprised of more than 161 distinct microarray
platforms. Interestingly, 95 diseases were found to have two or
more representative experiments in public data, even given
our constraint that each experiment was required to have
samples for both the disease and normal control conditions.
Although diseases important to public health, such as type 2
diabetes, are among the diseases with the most experiments, it
was possible to find replicate experiments for rare disorders,
such as essential thrombocythemia, in public data.
Quantifying and comparing disease conditions
For each of the 429 disease-associated experiments, we
computed a disease state vector, which represented the change
in expression in the disease condition relative to the normal
control condition for all measured genes. To evaluate the
effects of various data normalization and disease state
quantification methods, we created parallel sets of disease
state vectors using many different combinations of commonly
used normalization and quantification methods (see Materials
and methods for details), which we will refer to as pipeline
routings. For each of the 84 possible pipeline routings, we
computed all possible within-species, pair-wise correlations
between disease state vectors, which resulted in 36 417 distinct
correlation measures per pipeline routing (3 059 028 total
correlations). As a control, we also calculated these pair-wise
correlations after randomly shuffling tissue and disease
annotation labels.
We find the ability to establish a statistical concordance
between microarray experiments depends on the normal-
ization and disease state quantification methods chosen. In
our analysis, the subtractive approach to disease state
quantification, in which the gene expression values from the
normal state are simply subtracted from those in the respective
disease state, outperforms fold-change and t-test methods in
capturing disease concordance within and across tissues
(Supplementary Table S1). It is surprising that t-test methods
performed poorly in capturing disease concordance, as t-test-
based methods are among the most commonly used in
microarray data analysis. However, t-test based methods are
strongly influenced by estimates of gene-specific variance
(Breitling et al, 2004), therefore, it is likely that the t-test
approach suffered from the small sample sizes, characteristic
of a number of disease experiments in the public data. The
prominence of the subtractive methods may be explained by
the use of correlation as our concordance measure, and the
possibility that the magnitudes of critical differential gene
expression changes in the disease state are somehow
dampened by fold-change and t-test-based approaches. As an
alternative measure of disease signature robustness, we
computed ROC AUC distributions for each disease/tissue
category using the best performing method under correlation,
and we found that concordant experiments are also signifi-
cantly predictive of each other (Supplementary Figure S1).
Disease concordance versus tissue concordance
To gain a comprehensive picture of disease concordance across
microarray experiments, we evaluated whether correlations
between disease-associated experiments were driven by
tissue-specific gene expression. For each pipeline routing, the
resulting 36 417 pair-wise correlation coefficients were as-
signed to one of the four categories according to their disease
and tissue annotations. Under this scheme, we could evaluate
the distributions of correlations between experiments inwhich
both vectors measured the same disease from the same tissue
(Dþ/Tþ ), the same disease from different tissues (Dþ/T),
different diseases from the same tissue (D/Tþ ), or different
diseases from different tissues (D/T). Analysis of the
Fisher’s z transformed correlation coefficient distributions
between these categories revealed a significant degree of
variance among pipeline routings with regards to the strength
of the disease signal over the tissue signal. Figure 1 contrasts
the results between two pipeline routings. Figure 1a shows a
pipeline routing in which correlation coefficients between
disease state vectors measuring the same disease from the
same tissue (Dþ/Tþ ) were significantly greater than correla-
tions between different diseases in the same tissue (D/Tþ )
(Tukey’s HSD P-value¼1.151014). In contrast, the pipeline
routing in Figure 1b shows correlation coefficients with no
differences between Dþ/Tþ and D/Tþ .
Formany pipeline routings, we found that the distribution of
correlations between disease state vectors, measuring the
same disease in a different tissue (Dþ/T), was often higher
than the distributions of correlations between disease
state vectors measuring a different disease in the same tissue
(D/Tþ ). Such a case is illustrated by the pipeline routing in
Figure 1a. These cases seem to imply that the signal of disease
concordance across microarray experiments is stronger than
the signal of tissue concordance.
To determine whether this observation could be generalized
across all pipeline routings, we plotted the median disease/
tissue category correlation coefficients for each of the 84
pipeline routings, along with the medians computed by
randomly shuffling annotation labels for each pipeline routing
(Figure 2). We find support for a general trend indicating that
the disease concordance signal was generally distinguished
above the level of the tissue concordance signal irrespective of
the data processing techniques applied.
The relative strength of the disease concordance signal over
the tissue concordance signal is a compelling finding with
substantial implications for the general practice of microarray
meta-analysis. One might have expected a relatively strong
degree of concordance between diseases experiments sampled
from the same tissue, given the number of genes likely to be
involved in tissue-specific biology (Kilpinen et al, 2008;
Shyamsundar et al, 2005). However, we have shown here that
disease conditions seem to have synchronized gene expression
changes across different tissues. Figure 3 illustrates the
symmetry in gene expression that can be observed for the
same disease across tissues. In Figure 3, we observe a
significant concordance between two experiments measuring
Disease signatures
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Huntington’s disease from different tissues, whereas there is
relatively minimal concordance observed between two experi-
ments measuring distinct diseases from the same tissue. This
could occur as the result of the systemic nature of the disease
pathogenesis. For example, a localized gene expression
signature involving INF-g, TNF-a, IL-2, IL-12, and IL-18 genes
might signify the formation of noncaseating granulomatous
lesions across multiple tissue types in systemic sarcoidosis
(Kettritz et al, 2006; Nunes et al, 2007). It is also possible that
there are limited channels through which disparate tissues
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Figure 2 An aggregate view of the median correlation across the four disease/tissue categories for all 84 possible pipeline routings. Vertical black bars represent the
s.e.m. correlation. The colored lines connect disease/tissue category medians computed using the same pipeline-routing. Although certain pipeline routings perform
better than others at establishing disease concordance, we observe a general trend indicating that the disease signal is stronger than the tissue signal regardless of the
analytical methods used.
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Figure 1 Boxplots comparing the distributions of the Fisher’s z transformed correlation coefficients across the four disease/tissue categories. Boxplot in (A) shows
a pipeline routing using parameters (NoNorm/NoCollapse/NoAggregate/SubtractiveDiff), which resulted in a significant separation of the same disease, different tissue
category (Dþ /T) from the different disease, same tissue category (D/Tþ ). Boxplot in (B) shows a pipeline routing using parameters (NoNorm/NoCollapse/
NoAggregate/TtestDiff), which resulted in a distribution similar to that produced by the randomized data using the same pipeline routing parameters.
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communicate, and perhaps disease conditions essentially
maximize the amplitude of communication in one type of
channel to the effect of synchronizing the genes mediating the
communication. For example, hyperglycemia in diabetes
might maximize the amplitude of signaling and pathways
involved in the regulation of insulin, glucagon, and other
hormones across muscle, hepatic, and pancreatic tissues
(Bansal and Wang, 2008; Yano et al, 2008). Recently, Dobrin
et al (2009) discovered that tissue-to-tissue co-expression sub-
networks in mouse models for obesity were more highly
connected than within-tissue networks, lending credence to
this assertion. Perhaps another explanation for the observed
lack of tissue concordance is greater variation in tissue-specific
gene expression than previously acknowledged between and
among populations represented in public data (Whitehead and
Crawford, 2005).
We acknowledge several limitations to the approach taken
by this study. Foremost, we acknowledge that experimental
investigators will generally draw samples from tissues that are
relevant to the disease condition under study. Therefore, we
cannot assert that disease concordance would be maintained
in samples drawn from tissues that would not commonly be
chosen in the study of a disease. Nonetheless, the primary
purpose of this investigation was to make observations from
the data currently available in public repositories. We also
recognize that the results are dependent on the quality and
accuracy of the vocabulary annotations attributed to the
experiments, though here, we manually validated our annota-
tions. We also acknowledge that these vocabularies are
dynamic, in which a term describing a single tissue might be
split into two different concepts in the future, and that the
vocabulary structure may have a bearing on the interpretation
of the results. However, we determined that there was no
significant relationship between vocabulary structure and
observed correlation values (Supplementary Figure S2).
The findings of this study raise several important implica-
tions for the study of human disease and the role of public data
in translational research. With the understanding of a general,
trans-tissue disease concordance across the public microarray
data, it is now reasonable to undertake efforts to incorporate
these data in new systems models for disease pathology across
multiple tissues and organ systems. One possible utility would
be in biomarker discovery, in which the traditional practice
begins with a disease condition of interest and applies
molecular quantification techniques to discover putative
molecular markers that signify some aspect of the molecular
pathology. Instead, a broader systems view of disease derived
from public data would serve as a filter to restrict costly efforts
in biomarker discovery and validation of the space of
molecular components and phenomena that are unique to
the disease condition under study (Dudley and Butte, 2009).
Furthermore, the trans-tissue nature of disease concordance
suggests that it is reasonable to leverage public data to
search for biomarkers in more peripheral cells and fluids, such
as those found in blood and urine. This potential is illustrated
in Supplementary Figure S3, in which a microarray
experiment measuring type 2 diabetes (T2D) in the blood is
clustered with a core set of experiments measuring various
diseases from skeletal muscle. Not only do the diseases
cluster consistently within tissue, but also the experiment
measuring T2D in peripheral blood is clearly matched with
the experiment measuring T2D in muscle. Future study
should seek to model relationships between primary affected
tissues and peripheral fluids within the public data to
determine whether the potential demonstrated in Supplemen-
tary Figure S3 can be generalized across a broad range of
human diseases.
These findings also suggest support for experimental
designs that are inclusive of both newly generated data and
relevant data available from public data repositories. We
previously showed that the integration of 49 obesity-related,
genome-wide experiments significantly improved the predic-
tive capability for discovering obesity-associated genes (Eng-
lish and Butte, 2007), and the results from the study detailed
here validates a similar inclusive approach for every disease
represented in public data. Furthermore, major research is
presently underway by others to characterize sub-types of
clinically heterogeneous diseases such as breast cancers,
which are observed to show a great deal of variance with
regards to response to therapeutics and patient outcomes
(Weigelt et al, 2008; Wirapati et al, 2008). We argue that when
investigating the drivers of molecular concordance between
diseases, public experiments should be seen as opportunities
to allow for new directions in research into the shared
molecular pathophysiology of disease, which might offer a
more concise molecular characterization of the heterogeneity
observed within diseases or disease categories.
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Figure 3 Symmetry of disease-state gene expression for the same disease in
different tissues (Dþ /T) versus different diseases in the same tissue (D/Tþ ).
The colors indicate the direction of change in the expression of a gene in the
disease state relative to the normal control state, in which green indicates
upregulation of disease, and red indicates downregulation of disease. Here we
observe that the differential expression concordance between Huntington’s
disease in the brain (GDS2169) and blood (GDS1331) is much more extensive
than that observed between type 2 diabetes (GDS162) and Duchenne’s
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With the growing set of publicly available molecular
measurement data, biological and clinical investigators are
now enabled to ask new questions about the global properties
of human disease, and to buildmulti-tissue systemsmodels for
disease pathophysiology. Future studies in this area are likely
to impact our fundamental understanding of the molecular
bases of human disease, the repurposing of therapeutics across
disease conditions, or even lead to a completely new system of
human disease classification founded on molecular character-
istics, rather than symptoms and anatomy.
Materials and methods
Discovery and annotation of disease experiments
Gene expression microarray experiments in the NCBI GEO character-
izing human disease conditions were automatically identified using a
previously published method (Butte and Chen, 2006). Briefly, Medical
Subject Heading (MeSH) terms attributed to publications associated
with GEO experiments (accessed 26 November 2007) were evaluated
for disease concepts using the Unified Medical Language System
(UMLS) (release 2007AC) (Bodenreider, 2004). Each of these experi-
mental data sets determined to be relevant to a human disease, based
on associated MeSH disease concepts, was subject to an automated
annotation of the disease condition, the tissue or biological substance
from which the samples were derived, and whether or not the
experiment measured a normal control state complimentary to the
annotated disease state. The automated annotation step was carried
out using a previously published method that analyzes particular
annotations in a GEO DataSet (GDS), which is a higher-order
representation of an experiment (GSE) in GEO that groups experi-
mental samples into logical subsets (e.g. ‘control’ and ‘treatment’)
using a free-text vocabulary (Dudley and Butte, 2008). Disease and
tissue annotations were manually reviewed in a post-processing step
to ensure accuracy.
Our resulting data set incorporated 238 diseases studied across 385
GEO DataSets comprising 8435 individual microarrays, studied in
122 tissues.
To evaluate the hypothesis of a general disease concordance
independent of tissue type, we constructed an extensive computational
analytic pipeline (Box 1). The analytic pipeline comprised several
processing step, with a final step that calculates statistics from the
aggregate microarray experiments after they have been processed be
previous steps in the pipeline. For each run of the pipeline, called a
pipeline routing, our entire annotated set of 8435 microarrays is
offered as input data, and a number of available option parameters is
fixed before execution.
Pipeline step 1: normalize values
For each microarray platform represented in the set of disease-
associated experiments, we updated the mappings between platform-
specific probe identifiers and Entrez Gene identifiers in an automated
manner using the AILUN system (Chen et al, 2007). Then, for each
experiment, we derived two new sets (i.e. disease and control) of
normalized microarrays using three normalization methods. In the
first method, we rank-normalized the probes per array by assigning a
rank value to each probe on the basis of the rank of the measured
intensity relative to all other probes on the array (RankNorm). To
account for the fact that the number of probes differs among array
platforms, we divided the rank values by the total number of probes to
scale them between zero and one. In the second normalization
method, we median centered the arrays by shifting the probe intensity
values in each array such that the median value across all probes was
set to zero if the data were in log scale, or set to one if the data were
untransformed (CenterNorm). This normalization approach makes
the assumption that the expression levels of themajority of genes is not
expected to change significantly between conditions. A third option
was to simply use the unprocessed expression values obtained directly
from GEO (NoNorm). It is important to note that in many cases, the
raw expression values obtained from GEO may already be normalized
using one of many possible methods. Therefore, in the context of this
study, the concept of normalization is more representative of
experiment-wise normalization rather than normalization of truly
raw microarray data usually found in CEL data files.
Pipeline step 2: collapse probes
In many cases, a microarray platform was found to have multiple
probes reporting for a single Entrez GeneID (e.g. probes 216066_at and
215869_at on the Affymetrix Hu133v2.0 both map to Entrez GeneID
19). We designed the pipeline to offer two different options for
handling such cases. The first option was to simply retain the multiple
mappings (NoCollapse), which impacts downstream pipeline step 3
(Aggregate Arrays) and step 4 (Disease State Quantification) by
increasing the number of expression values per gene when calculating
summary statistics across samples, or between disease and normal
conditions. The second option was to calculate the mean expression
value for all probes associated with a GeneID on a per chip basis, such
that each GeneID with multiple probes was assigned the mean
expression value of its associated probes (MeanCollapse).
Pipeline step 3: aggregate arrays
This analysis only incorporated GEO experiments that offered replicate
samples (i.e. n41) for both control and disease conditions. Therefore,
we designed the pipeline to offer several different options for handling
sample replicates. In all cases options are applied within a condition
only (i.e. normal control samples could only be merged with other
normal control samples), and the merging refers to the merging of
expression values across samples on a per-gene basis. The first option
is to take the mean value for a gene across samples (MeanAggregate).
The second option is to take the median value for a gene across
samples (MedianAggregate). The third option is to take the maximum
expression value for a gene across samples (MaxAggregate). The
fourth option is to take the minimum expression value for a gene
across samples (MinAggregate). Finally, there is the option to leave the
replicate samples unmerged (NoAggregate). The sample merging step
is not available when the t-test option is used in pipeline step 4
(Disease State Quantification) because the t-test requires n41 samples
in each condition.
Pipeline step 4: disease state quantification
We define a disease state vector as a quantification of the change in
expression in the disease condition relative to the control condition, for
all genes measured on the microarray platform. In this way, a disease
state vector represents a quantity of change from control to disease for
all measured genes. The pipeline was designed to offer three different
options for quantifying the disease state represented in an experiment.
The first option is to compute the subtractive difference in expression
between the disease and control condition by simply subtracting the
expression values for the control from the respective disease values
(SubtractiveDiff). The second option is to compute the fold change in
expression between the disease and control condition by computing
the log of the ratio of the disease expression value over the control
expression value (FoldDiff). The third option computes a t-test statistic
between the expression values in the control condition and the
expression values in the disease condition (TtestDiff). The P-value of
the t-tests were retained as the quantification of the change in
expression between control and disease if the expression values for a
particular microarray platform were log-transformed, the subtractive
differencewas calculated as a ratio, and the fold changewas calculated
using the simple difference. If the experiment arrives at this step
without the samples merged, and if either the subtractive or fold
change option is selected, the pipeline computes all pair-wise
differences between samples for all measured genes using the chosen
method to build a distribution of quantified differences. The pipeline
then offers the option to take either the mean or the median value for
this distribution as the quantified difference in expression. If the
Disease signatures
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experiment arrives at this stepwith the samplesmerged, then the t-test
quantification option is disabled.
Pipeline step 5: computing disease concordance
This step proceeds once all the experiments have passed through
pipeline steps 1–4; at that point the resulting disease state vectors are
aggregated for disease concordance analysis. In this step, all possible
pair-wise correlations between the 429 disease state vectors are
computed. These 36 417 pair-wise correlations are then grouped into
four categories defined by the disease condition and by the source
biological tissue:
Within-disease/within-tissue (Dþ /Tþ )
Pair-wise correlations were assigned to this category if both disease
state vectors were annotated as measuring the same disease from the
same source tissue (n¼233).
Within-disease/between-tissue (Dþ /T)
Pair-wise correlations were assigned to this category if both disease
state vectors were annotated as measuring the same disease, but the
samples were acquired from different source tissues (n¼172).
Between-disease/within-tissue (D/Tþ )
Pair-wise correlations were assigned to this category if both disease-
state vectors were annotated as being acquired from the same source
tissue, but measured different diseases (n¼882).
Between-disease/between-tissue (D/T)
Pair-wise correlations were assigned to this category if both disease-
state vectors were annotated as measuring different diseases, and the
samples were acquired from different tissues (n¼35130).
All correlations were computed using Spearman’s rank-based
correlation to mitigate potentially confounding effects of between-
platform and between-lab measurement variation, and also due to the
fact that the normality of expression changes in disease state vectors
could not be assumed across all platforms and conditions.
The pipeline then tests for a significant difference in the distribution
of correlations between comparison categories by converting the
correlation values in each category to Fisher’s z-scores and carrying
out a one-way ANOVA. Given that a significant rejection of the null
hypothesis in a one-way ANOVA will support the alternative
hypothesis that, at least, one mean is different, a pair-wise evaluation
of differences in distributions was also carried out by applying Tukey’s
Honest Significant Difference (HSD) test to the Fisher’s z-score
distributions in each category.
As an additional control, the pipeline derives a random distribution
of correlations for each disease/tissue category by carrying out ten
rounds of randomization, in which the disease and tissue labels for all
experiments were shuffled before computing correlations and statis-
tical tests.
Supplementary information
Supplementary information is available at the Molecular Systems
Biology website (www.nature.com/msb).
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